Panbela Therapeutics Statistics
Share Statistics
Panbela Therapeutics has 5.25M shares outstanding. The number of shares has increased by -29.1% in one year.
| Shares Outstanding | 5.25M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.85M |
| Failed to Deliver (FTD) Shares | 185 |
| FTD / Avg. Volume | 2.02% |
Short Selling Information
The latest short interest is 106.97K, so 2.2% of the outstanding shares have been sold short.
| Short Interest | 106.97K |
| Short % of Shares Out | 2.2% |
| Short % of Float | 2.2% |
| Short Ratio (days to cover) | 0.07 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.06.
| PE Ratio | 0 |
| Forward PE | -0.06 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | n/a |
Enterprise Valuation
Panbela Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.25, with a Debt / Equity ratio of -1.1.
| Current Ratio | 0.25 |
| Quick Ratio | 0.25 |
| Debt / Equity | -1.1 |
| Total Debt / Capitalization | 1.07K |
| Cash Flow / Debt | -4.86 |
| Interest Coverage | 161.81 |
Financial Efficiency
Return on equity (ROE) is 5.36% and return on capital (ROIC) is -10520.48%.
| Return on Equity (ROE) | 5.36% |
| Return on Assets (ROA) | -2.14% |
| Return on Capital (ROIC) | -10520.48% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -3.61M |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -186.00K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -96.61% in the last 52 weeks. The beta is 0.94, so Panbela Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.94 |
| 52-Week Price Change | -96.61% |
| 50-Day Moving Average | 0.34 |
| 200-Day Moving Average | 0.42 |
| Relative Strength Index (RSI) | 47.77 |
| Average Volume (20 Days) | 9.14K |
Income Statement
In the last 12 months, Panbela Therapeutics had revenue of $0 and earned -$25.26M in profits. Earnings per share was $-232429.55.
| Revenue | 0 |
| Gross Profit | -25.65M |
| Operating Income | -51.29M |
| Net Income | -25.26M |
| EBITDA | -51.29M |
| EBIT | - |
| Earnings Per Share (EPS) | -232429.55 |
Balance Sheet
The company has $2.58M in cash and $5.19M in debt, giving a net cash position of -$2.62M.
| Cash & Cash Equivalents | 2.58M |
| Total Debt | 5.19M |
| Net Cash | -2.62M |
| Retained Earnings | -125.50M |
| Total Assets | 5.17M |
| Working Capital | -14.97M |
Cash Flow
In the last 12 months, operating cash flow was -$25.25M and capital expenditures $0, giving a free cash flow of -$25.25M.
| Operating Cash Flow | -25.25M |
| Capital Expenditures | 0 |
| Free Cash Flow | -25.25M |
| FCF Per Share | -232300.74 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
PBLA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -74977274.19% |
| FCF Yield | -1535.63% |
Analyst Forecast
The average price target for PBLA is $25, which is 7964.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $25 |
| Price Target Difference | 7964.5% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jan 18, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Jan 18, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -66.32 |
| Piotroski F-Score | 4 |